Letrozolo Pensa Pharma (Letrozole)

Letrozole blocks the aromatase enzyme, which converts adrenal and ovarian androgens into estrogen. By inhibiting this conversion, circulating estrogen levels fall dramatically, depriving estrogen‑dependent breast cancer cells of a key growth signal and thereby slowing disease progression.

The specific dose of Letrozolo Pensa Pharma is determined by the prescribing clinician based on the patient’s clinical status, renal and hepatic function, and treatment goals. Physicians follow established guidelines and adjust the regimen as needed for safety and efficacy.

Letrozolo Pensa Pharma is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding women, as letrozole may be excreted in milk and affect the infant.

To order Letrozolo Pensa Pharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Letrozolo Pensa Pharma (letrozole) is a non‑steroidal aromatase inhibitor with a long half‑life, offering once‑daily dosing. Compared with anastrozole, it may provide slightly greater estrogen suppression, while exemestane, a steroidal inhibitor, has a different binding profile. Choice depends on patient tolerance, prior therapy, and physician preference.

Letrozolo Pensa Pharma should be stored at ambient temperature, below 25 °C, in its original blister pack or bottle. Keep the product away from moisture, direct sunlight, and excessive heat to maintain potency throughout its shelf life.

Letrozolo Pensa Pharma is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the prescribing physician’s instructions regarding timing relative to meals.

Serious risks include severe liver injury, which may present as jaundice or elevated liver enzymes; bone fractures due to decreased bone mineral density; and deep‑vein thrombosis, which can cause leg swelling, pain, and potentially pulmonary embolism. Prompt medical attention is required if any of these occur.

Letrozolo Pensa Pharma should not be used by pregnant or breastfeeding women, premenopausal women, patients with severe hepatic impairment, or individuals with known hypersensitivity to letrozole or any excipients in the formulation. Clinicians must evaluate each patient’s medical history before initiating therapy.